Novel chemotherapeutic agents for the treatment of glioblastoma multiforme (Q35594029)

9 August 2017

1 reference

title

Novel chemotherapeutic agents for the treatment of glioblastoma multiforme (English)

1 reference

9 August 2017

1 reference

1 reference

2

Claus Belka

1 reference

9 August 2017

Verena Jendrossek

1

1 reference

PubMed ID

14640936

9 August 2017

Michael Bamberg

series ordinal

3

1 reference

PubMed ID

14640936

9 August 2017

language of work or name

English

0 references

publication date

1 December 2003

1 reference

Expert Opinion on Investigational Drugs

9 August 2017

1 reference

9 August 2017

12

1 reference

9 August 2017

12

1 reference

9 August 2017

1899-1924

1 reference

Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence and mortality.

9 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Gliomagenesis: genetic alterations and mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Malignant glioma physiology: cellular response to hypoxia and its role in tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Current and future developments in the use of temozolomide for the treatment of brain tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Chemotherapy in the treatment of recurrent glioblastoma multiforme: ifosfamide versus temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Novel chemotherapeutic agents for the treatment of brain cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Quantification of O6-methylguanine-DNA methyltransferase mRNA in human brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Human brain tumor O(6)-methylguanine-DNA methyltransferase mRNA and its significance as an indicator of selective chloroethylnitrosourea chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Temozolomide as second-line chemotherapy for relapsed gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

A comparison of treatment results for recurrent malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Survival of human glioma cells treated with various combination of temozolomide and X-rays

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

The current status of camptothecin analogues as antitumor agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-I: evidence for cell cycle-independent toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Modulation of irinotecan metabolism by ketoconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Determination of drug interactions occurring with the metabolic pathways of irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Induction of apoptosis in multi-drug resistant (MDR) human glioblastoma cells by SN-38, a metabolite of the camptothecin derivative CPT-11.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Matrix metalloproteinases and their biological function in human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Cost of Migration: Invasion of Malignant Gliomas and Implications for Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Roles of matrix metalloproteinases in tumor metastasis and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

New functions for the matrix metalloproteinases in cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Matrix metalloproteinases in tumor-host cell communication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Membrane-type matrix metalloproteinases (MT-MMPs): expression and function during glioma invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Expression of matrix metalloproteinases and their tissue inhibitors in human brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

In vivo glioma growth requires host-derived matrix metalloproteinase 2 for maintenance of angioarchitecture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Influence of VEGF-R2 inhibition on MMP secretion and motility of microvascular human cerebral endothelial cells (HCEC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Adenovirus-mediated expression of antisense MMP-9 in glioma cells inhibits tumor growth and invasion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Differential expression and localization of TIMP-1 and TIMP-4 in human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Ongoing trials with matrix metalloproteinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Phase II study of high central dose Gamma Knife radiosurgery and marimastat in patients with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Issues and progress with protein kinase inhibitors for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Combination of epidermal growth factor receptor targeted therapy with radiation therapy for malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Studies with ZD1839 in preclinical models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Expanding the therapeutic repertoire of epidermal growth factor receptor blockade: radiosensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Specific targeted therapy of chronic myelogenous leukemia with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Treatment with STI571, a tyrosine kinase inhibitor, for gastrointestinal stromal tumor with peritoneal dissemination and multiple liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Reversion of autocrine transformation by a dominant negative platelet-derived growth factor mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Dependence of autocrine growth factor stimulation in platelet-derived growth factor-B-induced mouse brain tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

TOR, a central controller of cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

A mammalian protein targeted by G1-arresting rapamycin-receptor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Mechanisms of angiogenesis in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Angiogenesis in brain tumors; pathobiological and clinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

A role for hypoxia and hypoxia-inducible transcription factors in tumor physiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Genetic and biologic progression in astrocytomas and their relation to angiogenic dysregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Antiangiogenesis: current clinical data and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Thalidomide: a new anticancer drug?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Thalidomide as an anti-angiogenic agent in relapsed gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Antiangiogenic therapy in brain tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Requirement of vascular integrin alpha v beta 3 for angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Squalamine: an aminosterol antibiotic from the shark

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

From bench to clinic with apoptosis-based therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Caspases: intracellular signaling by proteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Many cuts to ruin: a comprehensive update of caspase substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

The tyrosine kinase Lck is involved in regulation of mitochondrial apoptosis pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

A novel form of Epstein-Barr virus latency in normal B cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

PUMA, a novel proapoptotic gene, is induced by p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Rapid extracellular release of cytochrome c is specific for apoptosis and marks cell death in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Anti-apoptotic Bcl-2 proteins: structure, function and relevance for radiation biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

BCL-2 family protein expression in initial and recurrent glioblastomas: modulation by radiochemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

BCL-2 family proteins modulate radiosensitivity in human malignant glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Expression of bcl-2, bax and bcl-xl in human gliomas: a re-appraisal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Bcl-xL antisense oligonucleotides chemosensitize human glioblastoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Down-regulation of Bcl-2 and Bcl-xL expression with bispecific antisense treatment in glioblastoma cell lines induce cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Expression and biological activity of X-linked inhibitor of apoptosis (XIAP) in human malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

IAP family proteins--suppressors of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Safety and antitumor activity of recombinant soluble Apo2 ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Human astrocytic brain tumors express AP02L/TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Antitumor activity and prolonged expression from a TRAIL-expressing adenoviral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Adenoviral (full-length) Apo2L/TRAIL gene transfer is an ineffective treatment strategy for malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Molecular requirements for the combined effects of TRAIL and ionising radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Cytotoxic effects of alkyl-lysophospholipids in human brain tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Alkyl-lysophospholipids as anticancer agents and enhancers of radiation-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Membrane targeted anticancer drugs: potent inducers of apoptosis and putative radiosensitisers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Intracellular mediators of erucylphosphocholine-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Inhibition of proliferation and induction of differentiation in medulloblastoma- and astrocytoma-derived cell lines with phenylacetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Human malignant glioma cell lines are refractory to retinoic acid-mediated differentiation and sensitization to apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Role of translocation in the activation and function of protein kinase B

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Cellular survival: a play in three Akts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

Mechanism of activation and function of protein kinase B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1899

10.1517/13543784.12.12.1899

21 January 2018

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/d4hkxxcvyfc2nh6irathnc7uve

mapped directly with Wikidata item

30 July 2022

based on heuristic

Fatcat ID

release_d4hkxxcvyfc2nh6irathnc7uve

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/d4hkxxcvyfc2nh6irathnc7uve

mapped directly with Wikidata item

30 July 2022

based on heuristic

1 reference

https://api.fatcat.wiki/v0/release/d4hkxxcvyfc2nh6irathnc7uve